SCHEMBL264918

SCHEMBL264918

C[C@@]1(O)[C@H](O)[C@@H](COP(=O)(O)O)O[C@H]1c1coc2c(N)ncnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNPH1 O43598 1/20 0.42
PRKAB2 O43741 1/20 0.42
TRPM2 O94759 1/20 0.42
LDHA P00338 1/20 0.42
ADRB2 P07550 1/20 0.42
FBP1 P09467 1/20 0.42
SRC P12931 1/20 0.42
ADORA1 P30542 1/20 0.42
P2RY2 P41231 1/20 0.42
P2RY1 P47900 1/20 0.42
PRKAG1 P54619 1/20 0.42
PRKAA2 P54646 1/20 0.42
PDE4D Q08499 1/20 0.42
KCNH2 Q12809 1/20 0.42
PRKAA1 Q13131 1/20 0.42
PDE3A Q14432 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
P2RY11 Q96G91 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264779 0.91 P2RX3 (0.47) SRCP2RY2P2RY1SMN1; SMN2ENTPD1
SCHEMBL264673 0.87 P2RY1 (0.35) DNPH1PRKAB2TRPM2LDHAADRB2
SCHEMBL264550 0.84 CA12 (0.33) ENTPD1
SCHEMBL4962425 0.83 ADORA2A (0.48) ADORA1SMN1; SMN2
SCHEMBL13847085 0.83 ADORA2A (0.48) ADORA1SMN1; SMN2
SCHEMBL264091 0.83 ADORA2A (0.48) ADORA1SMN1; SMN2
SCHEMBL264092 0.83 ADORA2A (0.48) ADORA1SMN1; SMN2
SCHEMBL13843324 0.83 ADORA2A (0.48) ADORA1SMN1; SMN2
SCHEMBL280492 0.83 P2RX3 (0.46) SRCP2RY2P2RY1SMN1; SMN2ENTPD1
Hydrochloric Acid SCHEMBL3305326 0.82 ADORA2A (0.47) ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES BIOCRYST PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 US disclosed
US-8133870-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2012-03-13 US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-7429571-B2 Therapeutic furopyrimidines and thienopyrimidines BIOCRYST PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300200-A1 Therapeutic Furopyrimidines and Thienopyrimidines DPYD, TYMP, TYMS DNPH1 1249/4885PRKAB2 2304/4885TRPM2 4547/4885
US-20120213735-A1 THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES DPYD, TYMP, TYMS DNPH1 1249/4885PRKAB2 2304/4885TRPM2 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.